Search

The U.S. Supreme Court has declined to block a FDA rule that allows the abortion pill mifepristone to be prescribed via telehealth and mailed, maintaining access to a medication used in over 60% of U.S. abortions, amidst ongoing legal challenges from several Republican-led states seeking to restrict its availability. #AbortionRights #Telehealth #FDARegulations #US #LA #TX #FL #MO #KS #ID #HI #VA #WV #NC #NY #CA

The U.S. Supreme Court has temporarily upheld a 2023 FDA rule allowing the abortion pill mifepristone to be prescribed via telehealth and mailed, despite ongoing legal challenges from conservative states aiming to restrict access to the medication. #AbortionRights #Telehealth #FDARegulations #US #LA #TX #FL #MO #KS #ID #HI #VA #WV #NC #NY #CA

U.S. cancer centers are rapidly trying to enroll patients in an early access program for daraxonrasib, a promising new pancreatic cancer drug from Revolution Medicines, following its FDA approval for expanded access after demonstrating a significant increase in survival rates in clinical trials. #PancreaticCancer #FDAApproval #CancerResearch #US #CA #NE

U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its recent FDA approval for expanded access, which comes after clinical trials showed it can double survival rates in advanced cases of the disease. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are urgently enrolling patients in an expanded access program for the promising pancreatic cancer drug daraxonrasib, which recently showed in clinical trials to significantly extend survival, while they await expected FDA approval amidst a surge of patient requests. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are rapidly trying to enroll patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its FDA-approved expanded access due to its significant survival benefits demonstrated in clinical trials, amidst a surge of patient requests and logistical challenges in managing the program. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are rapidly enrolling patients in an early access program for daraxonrasib, a promising pancreatic cancer drug from Revolution Medicines, after the FDA approved the program following positive trial results that showed the drug doubled patient survival, while oncologists face logistical challenges in managing patient requests and navigating the approval process. #CancerResearch #FDAApproval #PancreaticCancer #US

The departure of U.S. FDA Commissioner Dr. Marty Makary is seen as a positive shift amid turmoil in the biotech sector, yet analysts warn that the lack of steady leadership may lead to increased volatility and unpredictability within the agency until a permanent replacement is appointed. #Biotech #FDA #Leadership #US

On May 12, President Donald Trump announced the departure of Dr. Makary Marty as the head of the FDA, acknowledging the challenges he faced amid criticism over his opposition to flavored e-cigarette permits and abortion regulations, while confirming that Kyle Diamantas would serve as the interim leader until a permanent replacement is found. #FDA #TrumpAdministration #HealthPolicies #US #CN #GB

On May 12, President Donald Trump announced that Dr. Makary Marty, the head of the U.S. Food and Drug Administration (FDA), would resign after facing criticism over his opposition to flavored e-cigarettes and tightened abortion restrictions, with his deputy Kyle Diamantas set to take on the role temporarily. #TrumpAdministration #FDA #PublicHealth #US #CN #GB

Dr. Marty Makary resigned as the commissioner of the Food and Drug Administration amid pressure over his opposition to the authorization of fruit-flavored e-cigarettes, following a contentious tenure marked by clashes with powerful industries and criticism from public health leaders. #FDA #PublicHealth #Resignation #US

Dr. Marty Makary resigned as commissioner of the FDA amid controversy over the agency's authorization of fruit-flavored e-cigarettes, following weeks of pressure and opposition from within the administration, making way for acting commissioner Kyle Diamantas, who advocates for transparency in food regulations. #FDA #PublicHealth #RegulatoryReform #US

Dr. Marty Makary resigned as the commissioner of the FDA following pressure over the agency's authorization of fruit-flavored e-cigarettes and criticism from various sectors, including public health leaders and industry executives, amid concerns that his policies may favor anti-vaccine and tobacco interests. #FoodSafety #PublicHealth #FDA #US

Dr. Marty Makary resigned as the commissioner of the FDA amid pressure from the Trump administration and opposition to the authorization of fruit-flavored e-cigarettes, following a controversial tenure marked by conflicts with various industries and criticism from public health leaders. #FDA #PublicHealth #E-cigarettes #US

Dr. Marty Makary resigned as commissioner of the FDA amid controversy over the authorization of fruit-flavored e-cigarettes and growing tensions with various industries and public health leaders, with Kyle Diamantas appointed as acting commissioner. #FDA #PublicHealth #FoodSafety #US

Dr. Marty Makary, the FDA commissioner and supporter of the Make American Healthy Again Movement, faces termination by President Trump following conflicts over vaping regulations, the abortion pill, and drug approval denials, despite his efforts to improve the FDA and his previous successes in drug approvals. #HealthPolicy #FDA #VapingHealth #US

Dr. Marty Makary, the FDA commissioner known for his support of the Make American Healthy Again Movement, is facing dismissal by President Trump after clashes over vaping regulations, the abortion pill, and drug approvals, amid pressure from tobacco companies and abortion opponents. #HealthPolicy #FDA #DrugRegulation #US #CA

Dr. Marty Makary, the FDA commissioner and supporter of the Make American Healthy Again Movement, faces dismissal by President Trump following conflicts over vaping regulations, the abortion pill, and drug approval denials, amid growing pressure from various interest groups, including tobacco and anti-abortion advocates, despite his efforts to improve regulatory processes and speed up drug approvals. #HealthCare #FDA #DrugApproval #US

Dr. Marty Makary, the FDA commissioner, faces dismissal from President Trump due to conflicts over vaping regulations, the abortion pill, and drug application rejections, despite his efforts to improve agency morale and promote health initiatives. #Healthcare #FDA #DrugApproval #US